Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/265354
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

NOD1 in the interplay between microbiota and gastrointestinal immune adaptations

AutorFernández-García, Victoria CSIC ORCID; González-Ramos, Silvia CSIC ORCID; Martín-Sanz, Paloma CSIC ORCID ; García del Portillo, Francisco CSIC ORCID ; Moisés Laparra, José; Boscá, Lisardo CSIC ORCID CVN
Palabras claveNOD1
Microbiota
Microbe-associated molecular patterns
Gastrointestinal
Immunometabolism
Fecha de publicaciónsep-2021
EditorElsevier
Academia Press
CitaciónPharmacological Research 171: 105775 (2021)
ResumenNucleotide-binding oligomerization domain 1 (NOD1), a pattern recognition receptor (PRR) that detects bacterial peptidoglycan fragments and other danger signals, has been linked to inflammatory pathologies. NOD1, which is expressed by immune and non-immune cells, is activated after recognizing microbe-associated molecular patterns (MAMPs). This recognition triggers host defense responses and both immune memory and tolerance can also be achieved during these processes. Since the gut microbiota is currently considered a master regulator of human physiology central in health and disease and the intestine metabolizes a wide range of nutrients, drugs and hormones, it is a fact that dysbiosis can alter tissues and organs homeostasis. These systemic alterations occur in response to gastrointestinal immune adaptations that are not yet fully understood. Even if previous evidence confirms the connection between the microbiota, the immune system and metabolic disorders, much remains to be discovered about the contribution of NOD1 to low-grade inflammatory pathologies such as obesity, diabetes and cardiovascular diseases. This review compiles the most recent findings in this area, while providing a dynamic and practical framework with future approaches for research and clinical applications on targeting NOD1. This knowledge can help to rate the consequences of the disease and to stratify the patients for therapeutic interventions.
Descripción© 2021 The Author(s).
Versión del editorhttp://dx.doi.org/10.1016/j.phrs.2021.105775
URIhttp://hdl.handle.net/10261/265354
DOI10.1016/j.phrs.2021.105775
ISSN1043-6618
Aparece en las colecciones: (IIBM) Artículos




Ficheros en este ítem:
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

5
checked on 16-feb-2023

WEB OF SCIENCETM
Citations

5
checked on 05-mar-2023

Page view(s)

33
checked on 21-abr-2024

Download(s)

103
checked on 21-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons